Theragen Bio provides genome service to more than 700 domestic medical and research institutes over 40 countries abroad, being as a global genome service provider and AI-based biopharmaceutical company specializing in the development of the fourth-generation personalized anti-cancer drugs. Theragen Bio strives to realize precision medicine based on genomic technology, thereby providing the true hope and practical solutions for welfare and health of mankind.